Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study

M Kok¹, E P Winer², S Loi³

Affiliations

¹ Departments of Medical Oncology, Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
³ Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Electronic address: sherene.loi@petermac.org.

Free article

Editorial

M Kok et al. Ann Oncol. 2019.

Free article

. 2019 Jan 1;30(1):13-16.

doi: 10.1093/annonc/mdy473.

M Kok¹, E P Winer², S Loi³

¹ Departments of Medical Oncology, Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
³ Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Electronic address: sherene.loi@petermac.org.

No abstract available

Comment on

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P. Adams S, et al. Ann Oncol. 2019 Mar 1;30(3):405-411. doi: 10.1093/annonc/mdy518. Ann Oncol. 2019. PMID: 30475947 Clinical Trial.